Human Genome Sciences to redeem 3¾%, 5% convertible notes due 2007

By Angela McDaniels

Seattle, Nov. 8 - Human Genome Sciences Inc. said it will call all of its outstanding 3¾% convertible subordinated notes due 2007 and 5% convertible subordinated notes due 2007 for redemption on Dec. 1.

The redemptions will complete Human Genome Sciences' planned repurchase of all of its remaining outstanding subordinated notes due 2007, the company said.

Holders of the 3¾% notes will receive $1,006.30 in cash per $1,000 principal amount, plus accrued interest.

Holders of the 5% notes will receive $1,008.30 in cash per $1,000 principal amount, plus accrued interest.

In lieu of redemption, holders may convert their notes into Human Genome Sciences common stock at any time up to Nov. 30.

Human Genome Sciences is a Rockville, Md.-based pharmaceutical company that develops drugs that serve patients with unmet medical needs.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.